Clinical Characteristics of COVID-19 and the Value of Mulbsta Scoring System in Prognosis Evaluation

Abstract BackgroundCOVID-19, a worldwideinfectious disease, has killed more than 420000 people, whichis extremely harmful.MethodsIn this single-center retrospective study, we included the novel coronavirus pneumonia confirmed in our hospital. This study collected the basic information andclinical examination features.ResultsThe enrolled 704 patients were affirmed infected with 2019-nCoV by the test of throat swabs. There are 334 men and 369 women, and gender, age, combined with basic diseasesare distinct in diverse disease classification (p<0.05). From the symptom analysis, the proportion of fever over 38 degrees, dyspnea, fatigue, poor appetite and other symptoms is diverse in different types of diseases (p<0.05). As the severity of the disease increases, the median lymphocyte count decreases, C-reactive protein increase, erythrocyte sedimentation rateincrease, albumin decrease, pleural effusion increase, D-Dimer and NT-proBNP increase significantly (p<0.05).As the disease severity increases, the average value of MuLBSTA score obviously ascend (p<0.05), MuLBSTA scoring system predicts novel coronavirus pneumonia patients' prognosis is still insufficient, and may require additional indicators including anorexia, fatigue, C reactive protein, etc (p<0.05).ConclusionThe MuLBSTA evaluation system has certain value for the evaluation of the disease, but it needs to be improved.

Download Full-text

Retrospective analysis of the clinical features of outpatients with novel coronavirus in areas outside Wuhan, China

10.21203/rs.3.rs-25843/v1 ◽

2020 ◽

Author(s):

Yong-Tao Li ◽

Mei-Lian Peng ◽

Jia-dan Fu ◽

Li Liu ◽

Yong-zheng Guo ◽

...

Keyword(s):

Pathogen Detection ◽

Clinical Performance ◽

The Novel ◽

C Reactive Protein ◽

Early Screening ◽

Reactive Protein ◽

Ct Findings ◽

Epidemic Area ◽

Novel Coronavirus ◽

Lung Ct

Abstract Objective: The novel coronavirus pneumonia (COVID-19) has spread rapidly across the globe with the movement of people. How to diagnose COVID-19 quickly and accurately is a concern for all. We retrospectively assessed the clinical characteristics of patients with COVID-19 detected by outpatient screening in areas outside Wuhan, China, to guide early screening outside the epidemic area, to isolate and treat COVID-19-positive patients, and to control the spread of this virus in the region.Results: Among the 213 patients treated in the fever clinic of our hospital, 41 tested positive for novel coronavirus (2019-nCoV) and 172 were negative. Among the positive patients, 13 (31.7%) of the patients had been to Wuhan, while 28 (68.3%) had not been to Wuhan. There were 4 cases of clustering occurrence. The main symptoms exhibited by COVID-19-positive patients were fever (87.8%), cough (68.3%), and expectoration (34.1%). The C-reactive protein (CRP) levels were increased in 35 (85.3%) positive patients; the hydroxybutyrate dehydrogenase in the myocardial zymogram was increased in 22 positive patients (53.6%) and 38 negative patients (22.1%); computed tomography (CT) findings revealed lung lesions in all 41 positive patients (100%).Conclusion: We classified the patient population and analyzed the data to understand the early clinical performance of COVID-19. Our research illustrate that screening for COVID-19 outside Wuhan should focus on early symptoms such as fever and cough, in combination with lung CT findings, epidemiological history, and sputum pathogen detection to determine whether patients need further isolation.

Download Full-text

The impact of COVID-19 pandemic on the treatment of acute appendicitis in China

International Journal of Colorectal Disease ◽

10.1007/s00384-021-04031-4 ◽

2021 ◽

Author(s):

ZhiXue Zheng ◽

Jing Tao Bi ◽

Ya Qi Liu ◽

Xuan Cai

Keyword(s):

Acute Appendicitis ◽

White Blood Cells ◽

Onset Time ◽

The Novel ◽

C Reactive Protein ◽

Reactive Protein ◽

Number Of Patients ◽

Hospital Visits ◽

Novel Coronavirus ◽

The Impact

Abstract Objective This research aims to analyze the impact of the novel coronavirus pandemic on the hospital visits of patients with acute appendicitis. Methods The retrospective analysis was designed to look at the treatment of acute appendicitis in the Department of General Surgery in Beijing Jishuitan Hospital before and during the COVID-19 pandemic (2019–2020). Data was analyzed by the numbers of patients, sex, age, onset time, fever or not, laboratory examination, imaging test, and treatment. And we analyzed the differences between the “pre-COVID group” and “during-COVID group”. Results Compared with the year 2019, the number of acute appendicitis patients has diminished substantially during the COVID-19 pandemic (2020), but the number elevated with the control of the pandemic. Even if we did not find the differences of the treatment before and during the pandemic (P = 0.932), the onset time to emergency was significantly longer (P < 0.001), and more patients had showed fever (P < 0.001) during the COVID-19 pandemic. And the total number of white blood cells and C reactive protein level were significantly higher in 2020 than those in 2019 (P = 0.006, 0.003). And the same result was found in patients with appendiceal fecalith (P = 0.047). Conclusion During the pandemic of the new coronavirus pneumonia, the number of patients with acute appendix treatment dropped significantly, mainly because it took longer than before, and the condition was more severe. It can be seen that the new coronary pneumonia has a great impact on the patients’ medical treatment behavior, and the active prevention and treatment of the new coronavirus pneumonia is currently an important and urgent issue.

Download Full-text

Disparity in clinical characteristics between 2019 novel coronavirus pneumonia and leptospirosis

Open Medicine ◽

10.1515/med-2021-0262 ◽

2021 ◽

Vol 16 (1) ◽

pp. 494-497

Author(s):

BinBin Li ◽

ChunMiao Bao

Keyword(s):

White Blood Cells ◽

Length Of Hospital Stay ◽

C Reactive Protein ◽

Age And Gender ◽

Computed Tomographic ◽

Reactive Protein ◽

Clinical Difference ◽

And Gender ◽

Novel Coronavirus ◽

Chest Ct Scan

Abstract Objective A cluster outbreak of patients with similar symptoms and computed tomographic (CT) images of COVID-19 were diagnosed with leptospirosis. This study was aimed to identify the clinical difference between leptospirosis and COVID-19, providing evidence for strategy optimization. Methods A cohort of leptospirosis patients were collected and compared with age- and gender-matched COVID-19 cases in the epidemiological investigation, chest CT scan, laboratory tests, and length of hospital stay. Results Compared with COVID-19, contacting floodwater and lack of family clustering were features of leptospirosis in epidemiological assessment. In the laboratory test, higher level of white blood cells (WBCs: (10.38 ± 4.56) × 109/L vs (6.45 ± 1.95) × 109/L, p < 0.001), C-reactive protein (CRP: (138.93 ± 73.03) mg/L vs (40.28 ± 30.38) mg/L, p < 0.001), Creatine ((88.27 ± 35.16) mmol/L vs (63.31 ± 14.50) mmol/L, p < 0.001), and a lower level of platelet ((152.93 ± 51.93) × 109/L vs (229.65 ± 66.59) × 109/L, p < 0.001) were detected on patients with leptospirosis. Conclusion Given the epidemiological differences and seasonal prevalence, it is important to suspect leptospirosis in cases with a similar presentation of COVID-19. The clinical disparities may facilitate the therapeutic management of these two diseases.

Download Full-text

EXPRESS: Serum biomarkers for prediction of mortality in patients with COVID-19

Annals of Clinical Biochemistry International Journal of Laboratory Medicine ◽

10.1177/00045632211014244 ◽

2021 ◽

pp. 000456322110142

Author(s):

Rohit S Loomba ◽

Enrique G Villarreal ◽

Juan S Farias ◽

Gaurav Aggarwal ◽

Saurabh Aggarwal ◽

...

Keyword(s):

High Sensitivity ◽

Hepatic Function ◽

Pooled Analysis ◽

Cardiac Biomarkers ◽

Limited Information ◽

C Reactive Protein ◽

Acute Phase Reactants ◽

Reactive Protein ◽

Prediction Of Mortality ◽

Novel Coronavirus

Background There is limited information regarding the role of biomarker levels at predicting mortality in patients with the novel coronavirus pandemic (Covid-19). The purpose of this study is to determine the differences in serum biomarker levels in adults with Covid-19 who survived hospitalization from those who did not. Methods A comprehensive search was completed on PubMed, EMBASE, and Cochrane libraries to identify studies of interest. Endpoints of interest were blood counts, hepatic function test, acute phase reactants, cytokines and cardiac biomarkers. Results A total of 10 studies with 1,584 patients were included in the pooled analyses. Biomarkers that were noted to be significantly higher in those who died from Covid-19 (coronavirus disease 2019) included: white blood cell count, neutrophil count, C-reactive protein, high sensitivity C-reactive protein, procalcitonin, ferritin, D-dimer, interleukins 6, lactate dehydrogenase, creatine kinase, prothrombin time, aspartate aminotransferase, alanine aminotransferase, total bilirubin, and creatinine. Lymphocyte count, platelet count, and albumin were significantly lower in patients who died. Conclusion This pooled analysis of 10 studies including 1,584 patients identified significant differences in biomarkers on admission in patients who survived from those who did not. Further research is needed to develop risk stratification models to help with judicious use of limited healthcare resources.

Download Full-text

Chitinase-3-Like Protein 1 (YKL-40) Reflects the Severity of Symptoms in Atopic Dermatitis

Journal of Immunology Research ◽

10.1155/2017/5746031 ◽

2017 ◽

Vol 2017 ◽

pp. 1-5 ◽

Cited By ~ 7

Author(s):

Joanna Salomon ◽

Łukasz Matusiak ◽

Danuta Nowicka-Suszko ◽

Jacek C Szepietowski

Keyword(s):

Atopic Dermatitis ◽

Serum Level ◽

Serum Levels ◽

T Helper ◽

C Reactive Protein ◽

Blood Cell Count ◽

Reactive Protein ◽

Helper Response ◽

Severity Of The Disease

Chitinase-3-like protein 1 (YKL-40) is suggested to be associated with type 2 T helper response and atopy. The aim of the study was the evaluation of serum YKL-40 level in atopic dermatitis. The study was performed on 59 patients: 27 males and 32 females, aged from 18 to 64 years. The severity of the disease was assessed by the SCORAD and objective SCORAD indexes. The severity of pruritus was measured by the visual analogue scale. Blood samples were taken to examine serum level of YKL-40, total IgE level, C-reactive protein level, white blood cell count, and neutrophil count. YKL-40 serum levels were significantly higher in patients with atopic dermatitis compared to the controls. There was a positive correlation between YKL-40 concentration and SCORAD, objective SCORAD, and pruritus. This study has shown that YKL-40 serum level is increased in patients with atopic dermatitis and reflects the severity of symptoms.

Download Full-text

Study of the hematological scoring system and C-reactive protein (CRP) in determining Neonatal sepsis

Tropical Journal of Pathology and Microbiology ◽

10.17511/jopm.2020.i02.11 ◽

2020 ◽

Vol 6 (2) ◽

pp. 182-191

Author(s):

Dr Chandrahas Godbole ◽

◽

Dr. Sneha Ramdas Joshi ◽

Dr. Janice Jaison ◽

◽

...

Keyword(s):

Neonatal Sepsis ◽

Scoring System ◽

C Reactive Protein ◽

Reactive Protein

Download Full-text

Clinical and Laboratory Profiles of 75 Hospitalized Patients with Novel Coronavirus Disease 2019 in Hefei, China

10.1101/2020.03.01.20029785 ◽

2020 ◽

Cited By ~ 12

Author(s):

Zonghao Zhao ◽

Jiajia Xie ◽

Ming Yin ◽

Yun Yang ◽

Hongliang He ◽

...

Keyword(s):

T Cell ◽

Treatment Effectiveness ◽

Antiviral Treatment ◽

Laboratory Data ◽

Clinical Manifestations ◽

Nasopharyngeal Swab ◽

The Novel ◽

Reactive Protein ◽

Cell Counts ◽

Novel Coronavirus

AbstractThe outbreak of the novel coronavirus disease 2019 (COVID-19) infection began in December 2019 in Wuhan, and rapidly spread to many provinces in China. The number of cases has increased markedly in Anhui, but information on the clinical characteristics of patients is limited. We reported 75 patients with COVID-19 in the First Affiliated Hospital of USTC from Jan 21 to Feb 16, 2020, Hefei, Anhui Province, China. COVID-19 infection was confirmed by real-time RT-PCR of respiratory nasopharyngeal swab samples. Epidemiological, clinical and laboratory data were collected and analyzed. Of the 75 patients with COVID-19, 61 (81.33%) had a direct or indirect exposure history to Wuhan. Common symptoms at onset included fever (66 [88.0%] of 75 patients) and dry cough (62 [82.67%]). Of the patients without fever, cough could be the only or primary symptom. The most prominent laboratory abnormalities were lymphopenia, decreased percentage of lymphocytes (LYM%), decreased CD4+ and CD8+ T cell counts, elevated C-reactive protein (CRP) and lactate dehydrogenase (LDH). Patients with elevated interleukin 6 (IL-6) showed significant decreases in the LYM%, CD4+ and CD8+ T cell counts. Besides, the percentage of neutrophils, CRP, LDH and Procalcitonin levels increased significantly. We concluded that COVID-19 could cause different degrees of hematological abnormalities and damage of internal organs. Hematological profiles including LYM, LDH, CRP and IL-6 could be indicators of diseases severity and evaluation of treatment effectiveness. Antiviral treatment requires a comprehensive and supportive approach. Further targeted therapy should be determined based on individual clinical manifestations and laboratory indicators.

Download Full-text

Clinical cases of eculizumab use as a part of complex therapy in patients with severe COVID-19.

Тромбоз, гемостаз и реология ◽

10.25555/thr.2021.3.0987 ◽

2021 ◽

Author(s):

Р.А. Майер ◽

Б.А. Бакиров ◽

А.А. Набиева ◽

Д.А. Кудлай

Keyword(s):

Virus Disease ◽

Membrane Attack Complex ◽

Lung Ventilation ◽

Blood Analysis ◽

The Novel ◽

Reactive Protein ◽

Corona Virus ◽

Complex Therapy ◽

Novel Coronavirus ◽

Clinical Cases

Введение. В последние 2 года серьезной проблемой для всего мирового сообщества стало распространение новой коронавирусной (CoV) инфекции COVID-19 (COrona VIrus Disease-2019). Ввиду сложившихся событий в лечении COVID-19 активно стали применяться новые молекулы и уже зарегистрированные лекарственные препараты, доказавшие свою эффективность при других заболеваниях. Цель исследования: оценить эффективность применения препарата экулизумаб у пациентов с тяжелой формой течения COVID-19. Материалы и методы. Проанализированы 3 клинических случая применения препарата экулизумаб в составе комплексной терапии у пациентов с тяжелой формой течения COVID-19. Для оценки эффективности лечения проводился мониторинг основных клинико-лабораторных показателей, а также показателей, характеризующих воспалительный процесс при коронавирусной инфекции: общий анализ крови, биохимический анализ крови, проанализированы уровни таких показателей как ферритин, С-реактивный белок, интерлейкин-6, лактатдегидрогеназа и мембраноатакующий комплекс. Результаты. На фоне проводимой терапии выявлено снижение концентрации основных маркеров воспаления относительно исходных значений. Заключение. Комплексная терапия, включающая экулизумаб, облегчает течение заболевания, позволяет сократить длительность пребывания пациентов в отделении реанимации и интенсивной терапии, укорачивает срок их пребывания на искусственной вентиляции легких, тем самым снижая процент летальности. Background. In the past two years, the incidence of the novel coronavirus (CoV) infection COVID-19 (COrona Virus Disease-2019) has been a serious problem for the global community. Considering these circumstances, new molecules and already registered drugs that have proven their effectiveness in other diseases, began to be actively used in COVID-19 treatment. Objectives: to assess the effi cacy of eculizumab in patients with severe COVID-19. Patients/Methods. Three clinical cases of eculizumab use as a part of complex therapy in patients with severe COVID-19 have been analyzed. To assess the treatment efficacy, the main clinical and laboratory parameters and indicators of inflammatory process in coronavirus infection were monitored (clinical blood analysis, biochemical blood test, levels of ferritin, C-reactive protein, interleukin-6, lactate dehydrogenase and membrane attack complex). Results. Under the therapy we found the reduction of concentration of the main inflammation markers relative to the initial values. Conclusions. Complex therapy with eculizumab facilitates the course of the disease, reduces the stay duration of patients in the intensive care unit, shortens the period of artificial lung ventilation, thereby reducing the mortality rate.

Download Full-text